Corient Private Wealth LLC Purchases 17,144 Shares of Edwards Lifesciences Corporation $EW

Corient Private Wealth LLC boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 20.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 100,051 shares of the medical research company’s stock after buying an additional 17,144 shares during the quarter. Corient Private Wealth LLC’s holdings in Edwards Lifesciences were worth $8,547,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of EW. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences during the 3rd quarter worth $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $26,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $27,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $28,000. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $28,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Robert W. Baird boosted their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. TD Cowen reaffirmed a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research report on Tuesday, June 16th. Barclays reiterated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Finally, Evercore reissued an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a research report on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $95.96.

Insider Transactions at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 81,038 shares of company stock worth $6,683,255 over the last quarter. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Stock Up 3.0%

EW stock opened at $89.56 on Thursday. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $90.99. The company has a market cap of $51.57 billion, a PE ratio of 47.64, a price-to-earnings-growth ratio of 2.18 and a beta of 0.87. The business’s 50-day simple moving average is $83.93 and its 200 day simple moving average is $83.18. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.